U.S. markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
8.51-0.13 (-1.50%)
At close: 04:00PM EST
8.47 -0.04 (-0.47%)
After hours: 07:44PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close8.64
Bid8.47 x 2900
Ask8.50 x 2200
Day's Range8.45 - 8.72
52 Week Range7.73 - 13.30
Avg. Volume10,543,837
Market Cap9.85B
Beta (5Y Monthly)1.30
PE Ratio (TTM)12.89
EPS (TTM)0.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est11.36
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
11% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TEVA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Teva Pharmaceutical Industries
    Analyst Report: Teva Pharmaceutical Industries LimitedBased in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers.
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • Insider Monkey

    10 Best Stocks to Buy Today According to Value Investor David Abrams

    In this piece, we will take a look at the 10 best stocks to buy today according to value investor David Abrams. If you want to take a look only at the top five stocks in this list then head on over to 5 Best Stocks to Buy Today According to Value Investor David Abrams. […]

  • Motley Fool

    3 Turnaround Stocks That Can Bounce Back Big Time in 2022

    If we strictly looked at the performance of the major U.S. stock indexes, 2021 was a great year. While no investor enjoys seeing their stocks go in reverse, patience has a way of paying off handsomely in the stock market. In 2022, the following trio of turnaround stocks have the catalysts needed to bounce back in a big way.

  • Reuters

    Teva settles shareholder lawsuit over generic drug pricing for $420 million

    (Reuters) -Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs. Teva spokesperson Kelley Dougherty said the "vast majority" of the settlement will be funded by the company's insurers. "This resolution is in the overall best interest of Teva and the patients who continue to rely on us each day for the world’s largest portfolio of generics medicines," Dougherty said in an email.